TY - JOUR
T1 - Multidisciplinary management of Hunter syndrome
AU - Muenzer, Joseph
AU - Beck, M.
AU - Eng, C. M.
AU - Escolar, M. L.
AU - Giugliani, R.
AU - Guffon, N. H.
AU - Harmatz, P.
AU - Kamin, W.
AU - Kampmann, C.
AU - Koseoglu, S. T.
AU - Link, B.
AU - Martin, R. A.
AU - Molter, D. W.
AU - Rojas, M. V.Muñoz
AU - Ogilvie, J. W.
AU - Parini, R.
AU - Ramaswami, U.
AU - Scarpa, L. M.
AU - Schwartz, I. V.
AU - Wood, R. E.
AU - Wraith, E.
PY - 2009/12
Y1 - 2009/12
N2 - Hunter syndrome is a rare, X-linked disorder caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase. In the absence of sufficient enzyme activity, glycosaminoglycans accumulate in the lysosomes of many tissues and organs and contribute to the multisystem, progressive pathologies seen in Hunter syndrome. The nervous, cardiovascular, respiratory, and musculoskeletal systems can be involved in individuals with Hunter syndrome. Although the management of some clinical problems associated with the disease may seem routine, the management is typically complex and requires the physician to be aware of the special issues surrounding the patient with Hunter syndrome, and a multidisciplinary approach should be taken. Subspecialties such as otorhinolaryngology, neurosurgery, orthopedics, cardiology, anesthesiology, pulmonology, and neurodevelopment will all have a role in management, as will specialty areas such as physiotherapy, audiology, and others. The important management topics are discussed in this review, and the use of enzyme-replacement therapy with recombinant human iduronate-2-sulfatase as a specific treatment for Hunter syndrome is presented.
AB - Hunter syndrome is a rare, X-linked disorder caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase. In the absence of sufficient enzyme activity, glycosaminoglycans accumulate in the lysosomes of many tissues and organs and contribute to the multisystem, progressive pathologies seen in Hunter syndrome. The nervous, cardiovascular, respiratory, and musculoskeletal systems can be involved in individuals with Hunter syndrome. Although the management of some clinical problems associated with the disease may seem routine, the management is typically complex and requires the physician to be aware of the special issues surrounding the patient with Hunter syndrome, and a multidisciplinary approach should be taken. Subspecialties such as otorhinolaryngology, neurosurgery, orthopedics, cardiology, anesthesiology, pulmonology, and neurodevelopment will all have a role in management, as will specialty areas such as physiotherapy, audiology, and others. The important management topics are discussed in this review, and the use of enzyme-replacement therapy with recombinant human iduronate-2-sulfatase as a specific treatment for Hunter syndrome is presented.
KW - Enzyme-replacement therapy
KW - Hunter syndrome
KW - Lysosomal storage diseases
KW - Mucopolysaccharidosis II
UR - http://www.scopus.com/inward/record.url?scp=71949110878&partnerID=8YFLogxK
U2 - 10.1542/peds.2008-0999
DO - 10.1542/peds.2008-0999
M3 - Review article
C2 - 19901005
AN - SCOPUS:71949110878
VL - 124
SP - e1228-e1239
JO - Pediatrics
JF - Pediatrics
SN - 0031-4005
IS - 6
ER -